Udvidet returret til d. 31. januar 2025

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Bag om mTOR Inhibition for Cancer Therapy: Past, Present and Future

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

Vis mere
  • Sprog:
  • Engelsk
  • ISBN:
  • 9782817805573
  • Indbinding:
  • Paperback
  • Sideantal:
  • 300
  • Udgivet:
  • 23. august 2016
  • Udgave:
  • 12016
  • Størrelse:
  • 155x235x0 mm.
  • Vægt:
  • 4686 g.
  • BLACK NOVEMBER
  Gratis fragt
Leveringstid: 8-11 hverdage
Forventet levering: 7. december 2024

Beskrivelse af mTOR Inhibition for Cancer Therapy: Past, Present and Future

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.
Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

Brugerbedømmelser af mTOR Inhibition for Cancer Therapy: Past, Present and Future



Find lignende bøger
Bogen mTOR Inhibition for Cancer Therapy: Past, Present and Future findes i følgende kategorier:

Gør som tusindvis af andre bogelskere

Tilmeld dig nyhedsbrevet og få gode tilbud og inspiration til din næste læsning.